AI in Pharma: What the Research Says vs What Scientists Say in Real Life
- sharonshieldsconsu
- Jul 23
- 9 min read
If you read recent scientific reviews on artificial intelligence (AI) in the pharmaceutical industry, you get a clear message: AI is transforming drug discovery, clinical development, manufacturing, and safety.¹⁻⁵
If you talk to bench scientists, clinical teams, or data scientists over coffee, you often hear a more complicated story: pockets of impressive success, a lot of incremental improvements, and quite a few stalled pilots.
Both perspectives are true. They’re just looking at the same phenomenon from different angles.
This article compares published research on AI in pharma with anecdotal, on‑the‑ground experience, and suggests how to use both when deciding where and how to invest in AI.
In what follows, I’ll walk through the major parts of the pharma value chain—discovery, development, manufacturing, and safety—and compare what recent reviews report with what practitioners describe in day‑to‑day work. The goal isn’t to declare one perspective right and the other wrong, but to show how both together give you a more useful picture than either alone.
1. Overall Tone: Cautious in Papers, Mixed but Vivid in Practice
What the literature says
Recent reviews are broadly optimistic but careful in their wording:
A 2020 review in Drug Discovery Today notes that AI in drug discovery and development “reduces human workload” and can help teams “achieve targets in a short period,” but emphasizes that real‑world use is still emerging and constrained by data and validation needs.¹
A 2024 review on The Pharmaceutical Industry’s Future: How Artificial Intelligence‑Enabled Technologies Are Transforming the Sector concludes that AI accelerates drug discovery, improves manufacturing, and strengthens post‑marketing surveillance—but repeatedly uses phrases like “can potentially,” “shows promise,” and "early evidence suggests."
Another 2024 article on Artificial Intelligence in Pharmaceutical Innovation stresses that AI can rapidly analyse biological and chemical data to identify compounds, predict efficacy and toxicity, and optimize clinical trial steps, while highlighting unresolved challenges around data quality, standardization, and regulation.³
The tone across these papers is measured: AI is important and increasingly useful, but authors are careful not to overclaim.
What scientists say informally
Conversations I have had with with people working inside pharma and biotech over the last year are more polarized and vivid:
Some teams report step‑change improvements:
“What used to take six months of computational work now takes a couple of weeks.”
“We can virtually screen millions of compounds and narrow down to a few hundred high‑value candidates for synthesis.”
Others describe much more modest gains:
“The tool looks great in demos, but our actual program timelines haven’t changed that much.”
“We ran pilots, but none of them made it into routine use because of integration and validation issues.”
In informal settings, people talk freely about failed pilots, organizational resistance, wasting time on tools that “died in validation.” These stories rarely appear in the formal literature.
Takeaway
Published research and real‑world anecdotes point in the same direction—AI is useful—but differ in emphasis. Papers present a clean, cautious trajectory; practitioners describe a messier, uneven reality. Keeping both in mind helps you calibrate expectations before committing to a specific tool or program.
2. Discovery and Preclinical Development: Documented Gains, Context‑Dependent Impact
What the research shows
AI’s most mature and well‑documented applications are in drug discovery and preclinical development. Key reviews highlight a common set of capabilities:
Virtual screening and hit identification
AI models (including deep learning) can prioritize compounds for binding, potency, and selectivity. The 2020 review by Paul et al. documents use of AI for high‑throughput virtual screening, hit identification, and scaffold hopping.¹
De novo molecular design
Generative models can propose novel molecules satisfying multiple constraints (potency, ADMET, synthetic accessibility). A 2023–2024 wave of reviews on AI‑enabled drug design reports that such models can “swiftly design leads” and optimize candidates with fewer iterative cycles.⁴˒⁵
ADMET and toxicity prediction
AI is widely used to predict absorption, distribution, metabolism, excretion, and toxicity early in the pipeline, helping shift attrition to earlier, cheaper stages.¹˒²˒⁴
Drug repurposing and target identification
Machine learning applied to omics and real‑world data can suggest new disease indications and prioritize targets.¹⁻³
Collectively, these sources conclude that AI shortens discovery cycles, improves candidate quality, and reduces the risk of late‑stage failure.¹⁻⁵
What practitioners see
Medicinal chemists, computational chemists, and data scientists generally agree with the direction of travel, but their descriptions are more situational:
Where data are rich and well‑curated (e.g., certain target classes or modalities), AI can:
Cut time spent on idea generation and prioritization
Reduce the number of synthesis/test cycles needed to reach a viable lead
Where data are sparse, noisy, or biased, models often:
Underperform expectations
Require heavy manual oversight
Struggle to generalize when a program moves beyond familiar chemical space or target biology
A common refrain is that AI tools are excellent rankers and triage engines, but not fully autonomous decision makers:
“The model ranks the list, but the chemists still choose what to make.”
“We saved time at the ‘which ideas to test’ step; the bottleneck is now assay capacity and biology.”
Takeaway
The literature emphasizes robust technical capabilities and case studies; practitioners confirm the value but stress that real impact on end‑to‑end timelines is highly context‑dependent and still limited by biology, assays, and infrastructure. If you’re evaluating AI tools for discovery, ask vendors not just what the model can do, but what data conditions it requires to perform at the level advertised.
3. “AI‑Discovered” Drugs: Proofs of Concept vs Everyday Reality
How reviews present them
High‑profile examples of “AI‑designed” molecules entering clinical trials are frequently cited in reviews as proof that AI can meaningfully accelerate drug R&D.²⁻⁵ These papers highlight:
Programs where AI‑generated small molecules advanced from target to clinical candidate in timelines shorter than historical norms
Cases where AI contributed to new target identification or repurposing decisions
These examples are used to support claims that AI is reshaping the therapeutic landscape and may significantly increase R&D productivity.⁴˒⁵
How insiders interpret them
Scientists and managers often take a more nuanced view. They acknowledge these as genuine accomplishments, but point out that:
Many programs come from companies built around AI, automation, and integrated data infrastructure—conditions not yet typical across the industry
It is difficult to isolate the effect of “AI” from other factors: highly focused teams, willingness to take risk, and streamlined governance
They also note survivorship bias:
The successful AI‑enabled programs become case studies and press releases
Numerous AI‑supported projects that stalled or were deprioritized never make it into the literature
Takeaway
Case studies of AI‑designed drugs are real and important, but they represent the leading edge, not the median experience. Reviews treat them as early signs of a new normal; practitioners treat them as exceptions that show what’s possible under ideal conditions. When benchmarking your own program against these stories, account for the organizational and infrastructure differences that may be just as important as the algorithms themselves.
4. Clinical Trials: Vision vs Current Deployment
What the literature envisions
Reviews on AI in clinical development describe a compelling future:
Patient selection and enrichment
ML models to identify patients most likely to respond or progress, improving power and reducing sample sizes.²˒³˒⁶
Site selection and recruitment forecasting
Algorithms that combine historical performance, demographic data, and EHRs to choose optimal sites and estimate enrollment rates.³
Adaptive and precision trials
Models that predict efficacy and toxicity in subpopulations, supporting adaptive designs and personalized dosing strategies.³˒⁶
Real‑world evidence and safety
Use of AI on EHRs, registries, and claims data for external controls, long‑term outcomes, and post‑marketing surveillance.²˒³˒⁶
It is worth noting that many of these results are retrospective demonstrations (“if this model had been used, we could have…”), frameworks, or pilot studies—not yet large sets of fully AI‑optimized trials.
What clinical and ops teams report
People working in clinical operations, biostatistics, and translational medicine often describe a more incremental reality:
Models for recruitment feasibility and site ranking are being used and can improve planning accuracy
ML‑driven analysis of safety data and real‑world evidence generates additional insights, particularly for pharmacovigilance
However:
Integration with hospital EHRs and diverse data sources is complex, slow, and often incomplete
Sponsors and regulators are cautious about basing core trial decisions on opaque models without strong prospective validation
Major sources of delay—regulatory approvals, contracting, supply chain, logistics—are only partially addressable by AI
Takeaway
The literature offers a relatively clear vision of AI‑optimized clinical trials. In practice, organizations see useful but narrow tools in specific tasks, and system‑level transformation is still in early stages. The most realistic near‑term wins are in well‑defined, high‑volume tasks like site feasibility scoring and adverse event triage—not in replacing the core scientific and regulatory judgment that drives trial design.
5. Manufacturing, Quality, and Pharmacovigilance: Closer Alignment
Evidence from publications
AI applications in manufacturing and safety tend to be more concrete and engineering‑oriented:
Process optimization and predictive maintenance
AI applied to sensor data to predict equipment failures and optimize operating conditions.²˒⁷
Real‑time quality control
Computer vision and ML for detecting defects, monitoring fill‑finish operations, or assessing packaging integrity.²˒⁷
Pharmacovigilance and safety signal detection
Natural language processing (NLP) and ML to process spontaneous adverse event reports, literature, and social media for earlier signal detection.²˒³˒⁷
A 2026 review on Artificial Intelligence in Pharmaceutical Sciences: Opportunities & Challenges notes that AI supports formulation design, process control, and quality improvement in regulated environments, albeit with significant validation overhead.⁷
What operations and safety teams experience
Here, published research and practice are relatively well aligned:
Manufacturing groups report tangible gains from AI‑driven anomaly detection and process control, often in the form of reduced deviations or better yield stability
Safety teams use NLP‑assisted pipelines to triage adverse event reports and literature, reducing manual workload and improving coverage
The main friction points are:
GxP compliance, model validation, and change control
The need to keep most systems as decision‑support rather than fully autonomous, at least in the near term
Takeaway
In manufacturing and pharmacovigilance, both literature and anecdotes converge on a story of incremental but measurable improvements—less glamorous than “AI‑designed drugs,” but often more mature and deployable today. For organizations looking for near‑term, lower‑risk AI wins, this is a reasonable place to start.
6. Data, Culture, and “Hidden Work”: Underplayed in Papers, Central in Practice
How papers treat it
Most reviews acknowledge, often in a few paragraphs, that:
AI depends on high‑quality, standardized, and interoperable data²˒³˒⁷
There are challenges with explainability, bias, and regulatory expectations³⁻⁵
However, these topics are usually presented as manageable constraints, not as the dominant source of difficulty.
How practitioners describe it
Inside organizations, data and cultural issues often overshadow algorithmic concerns entirely:
Data:
“Getting access to clean, labelled data took 12–18 months; training the model took two weeks.”
Legacy systems (ELN, LIMS, clinical data warehouses) are fragmented and not designed for modern ML workflows.
Culture and workflows:
Bench scientists, clinicians, and quality staff need substantial training to trust and use AI outputs. Many successful prototypes become residents of the “pilot graveyard” because:
No one owns long‑term maintenance
IT and validation teams are overloaded
The tool doesn’t fit naturally into existing decision workflows
These topics—data engineering, change management, governance—rarely get proportionate weight in high‑level academic overviews, but dominate internal conversations about why AI projects succeed or fail.
Takeaway
The non‑technical work of making AI actually usable—data pipelines, integration, training, governance—is consistently underemphasized in the literature but is the main bottleneck in practice. Before asking “which AI model should we use?”, it is worth asking “do we have the data infrastructure and change management capacity to deploy it?”
7. Why the Perspectives Differ—and How to Use Both
Different evidence, different biases
Published research tends to:
Focus on successful, publishable projects
Evaluate models on benchmarks and historical datasets
Emphasize technical advances and conceptual frameworks
Anecdotes and internal reports tend to:
Highlight memorable extremes (remarkable successes or painful failures)
Be highly context‑specific (particular therapeutic areas, specific companies)
Include organizational, regulatory, and cultural friction that papers mostly abstract away
When combined
Both agree on the direction: AI is adding real value and is here to stay across discovery, development, manufacturing, and safety.¹⁻⁷
They differ on magnitude and speed:
Papers sometimes imply faster and broader impact than many organizations currently experience
Practitioners report solid but uneven gains, strongest in well‑defined, data‑rich, narrow problems
Practical implications if you’re planning or evaluating AI in pharma
Use the research literature to:
Identify proven use cases (e.g., virtual screening, ADMET prediction, image‑based QC, NLP‑based pharmacovigilance)¹⁻³˒⁷
Understand state‑of‑the‑art methods and regulatory considerations
See what is feasible under relatively good conditions
Use practitioner experience to:
Gauge how hard implementation will be with your current data and IT stack
Anticipate hidden costs in validation, change management, and integration
Avoid over‑generalizing from a few high‑profile success stories
Set balanced expectations:
Expect high ROI from well‑scoped, data‑rich, assistive applications (ranking, triage, prioritization, anomaly detection)
Expect slower, more incremental change in heavily regulated or data‑poor areas, or where decisions are high‑stakes and require interpretability
Treat AI as a force multiplier for good science, good data, and good processes—not a replacement for them
The organizations most likely to get sustained value from AI in pharma are not necessarily those with the most sophisticated models. They tend to be those that invest equally in the unglamorous work: cleaning data, integrating systems, training people, and building governance structures that let good tools actually get used.
The gap between AI’s promise and its day‑to‑day reality in pharma isn’t just a technology problem. It’s a talent problem.
The organizations closing that gap fastest aren’t the ones with the biggest AI budgets. They’re the ones with scientists and leaders who understand both worlds: the biology and chemistry that drives drug discovery, and the data thinking and model literacy that makes AI actually useful in practice.
That profile is rare. And it’s in high demand.
Get in touch to discuss the best approach to hiring for AI-fluent scientific and leadership roles in pharma and biotech
References
Paul D, Sanap G, Shenoy S, et al. Artificial intelligence in drug discovery and development. Drug Discov Today. 2020. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC7577280/
Alami H, et al. The Pharmaceutical Industry’s Future: How Artificial Intelligence‑Enabled Technologies Are Transforming the Sector. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC12703384/
Hasan SS, et al. The Potential of Artificial Intelligence in Pharmaceutical Innovation: From Drug Discovery to Clinical Trials. 2024. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC12195710/
Sharma A, et al. Artificial intelligence in drug development: reshaping the therapeutic landscape. 2024. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC11851753/
Fleuren WW, et al. Artificial intelligence as a disruptive force in the pharmaceutical industry. 2024. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC12994533/
Various authors. AI and machine learning in clinical trial design and optimization. Available at: https://pubmed.ncbi.nlm.nih.gov/40573185/
Jha S, et al. Artificial Intelligence in Pharmaceutical Sciences: Opportunities & Challenges. 2026. Available at: https://pubmed.ncbi.nlm.nih.gov/42107050/
Comments